Fungal arthritis

Nervous System Disease ◽

Coccidioides Immitis ◽

System Disease ◽

Fungal Arthritis ◽

Life Threatening

Fungal infections of the musculoskeletal system are uncommon and diagnosis is often delayed. Infection is more common in the immunocompromised patient. The most important infections are due to candida species, Histoplasmosis capsulatum, Blastomycosis dermatiditis, and Coccidioides immitis. Amphotericin B remains the initial therapeutic agent of choice for many serious fungal infections, especially for those who are severely immunosuppressed, have life-threatening or central nervous system disease, or who have failed azole therapy.

Fungal arthritis

10.1093/med/9780199642489.003.0106 ◽

2013 ◽

Author(s):

Carol A. Kemper ◽

Stanley C. Deresinski

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Therapeutic Agent ◽

Fungal Infections ◽

Immunocompromised Patient ◽

Coccidioides Immitis ◽

System Disease ◽

Fungal Arthritis ◽

Life Threatening

Fungal infections of the musculoskeletal system are uncommon and diagnosis is often delayed. Infection is more common in the immunocompromised patient. The most important infections are due to candida species, Histoplasmosis capsulatum, Blastomycosis dermatiditis, and Coccidioides immitis. Amphotericin B remains the initial therapeutic agent of choice for many serious fungal infections, especially for those who are severely immunosuppressed, have life-threatening or central nervous system disease, or who have failed azole therapy.

Abstract #815: Massive Polyuria Due to Ewing’s Sarcoma-Associated Central Nervous System Disease

Endocrine Practice ◽

10.1016/s1530-891x(20)43662-6 ◽

2005 ◽

Vol 11 ◽

pp. 56

Author(s):

Farah Dawood-Farah ◽

Maryann Mugo ◽

Stephen A. Brietzke

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Nervous System Disease ◽

Raccoon Roundworm Infection Associated with Central Nervous System Disease and Ocular Disease — Six States, 2013–2015

MMWR Morbidity and Mortality Weekly Report ◽

10.15585/mmwr.mm6535a2 ◽

2016 ◽

Vol 65 (35) ◽

pp. 930-933 ◽

Cited By ~ 13

Author(s):

Anita D. Sircar ◽

Francisca Abanyie ◽

Dean Blumberg ◽

Peter Chin-Hong ◽

Katrina S. Coulter ◽

...

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Ocular Disease ◽

Nervous System Disease ◽

International Journal of Central Nervous System Disease

10.28933/ijcnsd ◽

2018 ◽

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Nervous System Disease ◽

Outbreak of Central Nervous System Disease Associated with Hand, Foot, and Mouth Disease in Japan during the Summer of 2000: Detection and Molecular Epidemiology of Enterovirus 71

Microbiology and Immunology ◽

10.1111/j.1348-0421.2002.tb02743.x ◽

2002 ◽

Vol 46 (9) ◽

pp. 621-627 ◽

Cited By ~ 130

Author(s):

Tsuguto Fujimoto ◽

Masatsugu Chikahira ◽

Shigeru Yoshida ◽

Hitomi Ebira ◽

Ayako Hasegawa ◽

...

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Molecular Epidemiology ◽

Enterovirus 71 ◽

Foot And Mouth Disease ◽

Mouth Disease ◽

Nervous System Disease ◽

System Disease ◽

Foot And Mouth

Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies

The Annual Review of Pharmacology and Toxicology ◽

10.1146/annurev-pharmtox-010919-023429 ◽

2020 ◽

Vol 60 (1) ◽

pp. 291-309 ◽

Cited By ~ 1

Author(s):

Jesse A. Stokum ◽

Volodymyr Gerzanich ◽

Kevin N. Sheth ◽

W. Taylor Kimberly ◽

J. Marc Simard

Keyword(s):

Central Nervous System ◽

Clinical Trials ◽

Nervous System ◽

Cerebral Edema ◽

Clinical Studies ◽

Ancient Egypt ◽

Nervous System Disease ◽

Pharmacological Treatments ◽

Cerebral edema, a common and often fatal companion to most forms of acute central nervous system disease, has been recognized since the time of ancient Egypt. Unfortunately, our therapeutic armamentarium remains limited, in part due to historic limitations in our understanding of cerebral edema pathophysiology. Recent advancements have led to a number of clinical trials for novel therapeutics that could fundamentally alter the treatment of cerebral edema. In this review, we discuss these agents, their targets, and the data supporting their use, with a focus on agents that have progressed to clinical trials.